Achieve Life Sciences (NASDAQ:ACHV – Get Rating) will be announcing its earnings results after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.79) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.02. During the same quarter in the previous year, the firm earned ($1.30) EPS. On average, analysts expect Achieve Life Sciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Achieve Life Sciences Stock Down 0.6 %
ACHV opened at $4.97 on Thursday. The company has a quick ratio of 9.40, a current ratio of 9.40 and a debt-to-equity ratio of 0.71. The firm has a 50 day moving average price of $5.64 and a 200-day moving average price of $6.72. Achieve Life Sciences has a twelve month low of $4.81 and a twelve month high of $10.09. The stock has a market capitalization of $48.12 million, a price-to-earnings ratio of -1.31 and a beta of 1.19.
Institutional Trading of Achieve Life Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACHV. Charles Schwab Investment Management Inc. purchased a new stake in Achieve Life Sciences during the first quarter valued at approximately $79,000. Raymond James & Associates purchased a new stake in Achieve Life Sciences during the first quarter valued at approximately $99,000. Finally, State Street Corp increased its holdings in Achieve Life Sciences by 26.9% during the first quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 3,970 shares during the last quarter. 37.27% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, Oppenheimer boosted their price objective on shares of Achieve Life Sciences from $23.00 to $27.00 in a report on Wednesday, April 27th.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Featured Stories
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
